Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Healthcare Triangle (HCTI) EBITDA (2020 - 2025)

Healthcare Triangle's EBITDA history spans 6 years, with the latest figure at -$4.5 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 48.79% to -$4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.1 million, a 30.22% increase, with the full-year FY2025 number at -$9.5 million, up 29.39% from a year prior.
  • EBITDA hit -$4.5 million in Q4 2025 for Healthcare Triangle, down from -$1.9 million in the prior quarter.
  • Over the last five years, EBITDA for HCTI hit a ceiling of $470000.0 in Q2 2021 and a floor of -$10.6 million in Q4 2022.
  • Historically, EBITDA has averaged -$2.6 million across 5 years, with a median of -$1.7 million in 2023.
  • Biggest five-year swings in EBITDA: tumbled 1024.68% in 2021 and later surged 87.48% in 2023.
  • Tracing HCTI's EBITDA over 5 years: stood at -$3.3 million in 2021, then crashed by 220.09% to -$10.6 million in 2022, then surged by 87.48% to -$1.3 million in 2023, then plummeted by 559.38% to -$8.8 million in 2024, then surged by 48.79% to -$4.5 million in 2025.
  • Business Quant data shows EBITDA for HCTI at -$4.5 million in Q4 2025, -$1.9 million in Q3 2025, and -$1.4 million in Q2 2025.